Axial Spondyloarthritis (axSpA) is a chronic inflammatory condition primarily affecting the axial skeleton, including the spine and sacroiliac joints, leading to persistent back pain and stiffness. The condition is characterized by inflammation in the sacroiliac joints.
The main types of axial spondyloarthritis (axSpA) include Ankylosing Spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). Ankylosing Spondylitis (AS) is a specific form of arthritis that affects the ligaments and joints in the spine. Commonly used over-the-counter anti-inflammatory medications, such as naproxen and ibuprofen, are often employed to alleviate pain, inflammation, and muscle stiffness, with the goal of delaying complications and spinal deformities. Various commercialized therapies are available for the treatment of axial spondyloarthritis, including anti-tumor necrosis factor therapy (TNF), anti-interleukin therapy (IL), and anti-janus kinase therapy (JAK). These therapies come in different dosage forms, such as tablets and injections, and are utilized for different types of treatments, including tumor necrosis factor (TNF) alpha inhibitors, non-steroidal anti-inflammatory drugs (NSAID), conventional disease-modifying anti-rheumatic drugs, glucocorticoids, and interleukin blockers. These treatments are distributed through different channels, including hospital pharmacies, retail pharmacies, and online pharmacy stores.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The axial spondyloarthritis (axSpA) market research report is one of a series of new reports from The Business Research Company that provides axial spondyloarthritis (axSpA) market statistics, including axial spondyloarthritis (axSpA) industry global market size, regional shares, competitors with an axial spondyloarthritis (axSpA) market share, detailed axial spondyloarthritis (axSpA) market segments, market trends and opportunities, and any further data you may need to thrive in the axial spondyloarthritis (axSpA) industry. This axial spondyloarthritis (axSpA) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The axial spondyloarthritis (axspa) market size has grown strongly in recent years. It will grow from $6.08 billion in 2024 to $6.56 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to improved diagnostic criteria, biological treatment advancements, rising disease awareness, genetic research advances, clinical trial progress.
The axial spondyloarthritis (axspa) market size is expected to see strong growth in the next few years. It will grow to $9.03 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to advancements in biomarker identification, tailored therapies, digital health integration, expanded treatment options, healthcare policy support. Major trends in the forecast period include early intervention strategies, patient-centric care, telemedicine and remote consultations, research on disease mechanisms, shared decision-making.
The forecast of 8.3% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. rheumatology care by inflating prices of IL-17 inhibitors and spinal MRI contrast agents developed in Denmark and Belgium, resulting in delayed inflammatory back pain treatment and higher specialty pharmacy costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The rising prevalence of spondyloarthritis is expected to be a driving force behind the growth of the axial spondyloarthritis (axSpa) market. Spondyloarthritis, a chronic condition primarily affecting the axial skeleton, such as the spine and sacroiliac joints, has seen an increase in cases linked to the aging population and spinal injuries resulting from minor falls or accidents. Various treatments aim at managing pain, controlling inflammation, and improving the quality of life for individuals suffering from axSpA. For example, according to Versus Arthritis's Musculoskeletal Health Report 2023, a UK-based charity supporting people with arthritis, approximately 60,000 individuals were affected by axial spondyloarthritis in 2022, with around 2,200 adults diagnosed annually with this condition. Hence, the rising prevalence of axial spondyloarthritis is a significant driver fueling the growth of the axSpa market.
The growing aging population is anticipated to drive the expansion of the axial spondyloarthritis (axSpA) market in the future. An aging population refers to a demographic shift where the proportion of elderly individuals within a population increases. Managing axSpA in older adults offers several benefits, including improved joint function and mobility, enhanced quality of life, prevention of spinal structural damage, reduced healthcare costs, prevention of disability, and optimized treatment approaches. For instance, in October 2022, the World Health Organization reported that by 2030, 1 in 6 people globally will be aged 60 or older, with this figure expected to double to 2.1 billion by 2050. Furthermore, in July 2023, Age UK, a UK-based charity, noted that there are currently 11 million people over the age of 65 in England, with this number projected to rise by 10% over the next five years and by 32% by 2043, equating to increases of 1.1 million and 3.5 million people, respectively. As a result, the rising aging population is fueling the growth of the axial spondyloarthritis (axSpA) market.
Product innovation stands out as a leading trend gaining traction in the axial spondyloarthritis (axSpA) market. Key companies in this field are actively developing novel drugs to maintain their market standing. For instance, in June 2023, UCB SA, a pharmaceutical company based in Belgium, obtained marketing authorization from the New European Commission for BIMZELX (bimekizumab). This medication is designed for treating active axial spondyloarthritis (axSpA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS) in adults exhibiting objective signs of inflammation indicated by elevated C-reactive protein. These approvals within the European Union represent the first global marketing authorizations for the treatment of axial spondyloarthritis using this drug.
Significant investments are a focal point for major companies operating in the axial spondyloarthritis (axSpA) market to gain a competitive advantage. Notably, the investment revolves around the development of Izokibep, a unique IL-17A inhibitor intended for managing inflammatory diseases such as psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA). For example, in September 2022, Acelyrin Inc., a biopharmaceutical company based in the US, announced a $300 million investment. Izokibep, a mimetic antibody simulating interleukin-17A (IL-17A), aims to overcome the limitations of monoclonal antibodies and has shown promising tolerability in clinical trials. This substantial investment is directed towards securing potential approvals for Izokibep as a treatment for various inflammatory conditions and advancing its clinical development. The company's commitment to pioneering immunology therapies and addressing unmet medical needs in treating inflammatory disorders is evident through its emphasis on securing significant funding and advancing the development of Izokibep.
In April 2022, Ampersand Health, a UK-based research company, entered into a partnership with UCB SA for an undisclosed amount. This collaboration is intended to benefit patients dealing with axial spondyloarthritis (axSpA) by leveraging the innovative digital solutions from Ampersand Health and the clinical expertise of UCB SA. The aim of the partnership is to enhance the management of symptoms for individuals with axial spondyloarthritis and improve their overall quality of life. UCB SA, the Belgium-based biopharmaceutical company involved in neurology and immunology therapies, is known for providing solutions in the field of axial spondyloarthritis.
Major companies operating in the axial spondyloarthritis (axSpA) market include Johnson and Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, Merck and Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca plc., Abbott Laboratories, GSK plc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, UCB S.A., Boehringer Ingelheim International GmbH., Horizon Therapeutics Public Ltd Co, Mitsubishi Tanabe Pharma Corporation, Ipsen Technologies Pvt Ltd., Kyowa Kirin Co. Ltd., Sun Pharmaceutical Industries Ltd., Acelyrin Inc., Nordic Bioscience A/S, Iroko Pharmaceuticals LLC
North America was the largest region in the axial spondyloarthritis (axSpA) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the axial spondyloarthritis (axspa) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the axial spondyloarthritis (axspa) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The axial spondyloarthritis (axSpA) market consists of revenues earned by entities by providing physical examinations, blood tests, magnetic resonance imaging (MRI) scans, and X-ray scans. The market value includes the value of related goods sold by the service provider or included within the service offering. The axial spondyloarthritis (axSpA) market also includes sales of analgesics, biologics, ibuprofen, naproxen, and diclofenac. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Axial Spondyloarthritis (axSpA) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on axial spondyloarthritis (axspa) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for axial spondyloarthritis (axspa) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The axial spondyloarthritis (axspa) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Types: Ankylosing Spondylitis (AS); Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
- 2) By Commercialized Therapies: Anti-Tumor Necrosis Factor Therapy (TNF); Anti-Interleukin Therapy (IL); Anti-Janus Kinase Therapy (JAK)
- 3) By Dosage Form: Tablets; Injections
- 4) By Treatment: Tumor Necrosis Factor (TNF) Alpha Inhibitors; Non-Steroidal Anti-Inflammatory Drugs (NSAID); Conventional Disease Modifying Anti-Rheumatic Drugs; Glucocorticoids; Interleukin Blockers
- 5) By End-Use: Hospital Pharmacies; Retailer Pharmacies; Online Pharmacy Stores
- Subsegments:
- 1) By Ankylosing Spondylitis (AS): Early-stage AS; Advanced-stage AS
- 2) By Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Symptomatic nr-axSpA; Asymptomatic nr-axSpA
- Companies Mentioned: Johnson and Johnson Private Limited; Pfizer Inc.; F. Hoffmann-La Roche AG; Merck and Co. Inc.; AbbVie Inc.; Novartis AG; Sanofi S.A; Bristol-Myers Squibb Company; AstraZeneca plc.; Abbott Laboratories; GSK plc.; Eli Lilly and Company; Takeda Pharmaceutical Company Limited; Gilead Sciences Inc.; Teva Pharmaceutical Industries Ltd.; Regeneron Pharmaceuticals Inc.; Biogen Inc.; Vertex Pharmaceuticals Incorporated; UCB S.A.; Boehringer Ingelheim International GmbH.; Horizon Therapeutics Public Ltd Co; Mitsubishi Tanabe Pharma Corporation; Ipsen Technologies Pvt Ltd.; Kyowa Kirin Co. Ltd.; Sun Pharmaceutical Industries Ltd.; Acelyrin Inc.; Nordic Bioscience A/S; Iroko Pharmaceuticals LLC
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Axial Spondyloarthritis (axSpA) Market Characteristics
3. Axial Spondyloarthritis (axSpA) Market Trends And Strategies
4. Axial Spondyloarthritis (axSpA) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
- 4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Axial Spondyloarthritis (axSpA) Growth Analysis And Strategic Analysis Framework
- 5.1. Global Axial Spondyloarthritis (axSpA) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Axial Spondyloarthritis (axSpA) Market Growth Rate Analysis
- 5.4. Global Axial Spondyloarthritis (axSpA) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Axial Spondyloarthritis (axSpA) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Axial Spondyloarthritis (axSpA) Total Addressable Market (TAM)
6. Axial Spondyloarthritis (axSpA) Market Segmentation
- 6.1. Global Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Ankylosing Spondylitis (AS)
- Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
- 6.2. Global Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Anti-Tumor Necrosis Factor Therapy (TNF)
- Anti-Interleukin Therapy (IL)
- Anti-Janus Kinase Therapy (JAK)
- 6.3. Global Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Tablets
- Injections
- 6.4. Global Axial Spondyloarthritis (axSpA) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Tumor Necrosis Factor (TNF) Alpha Inhibitors
- Non-Steroidal Anti-Inflammatory Drugs (NSAID)
- Conventional Disease Modifying Anti-Rheumatic Drugs
- Glucocorticoids
- Interleukin Blockers
- 6.5. Global Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Pharmacies
- Retailer Pharmacies
- Online Pharmacy Stores
- 6.6. Global Axial Spondyloarthritis (axSpA) Market, Sub-Segmentation Of Ankylosing Spondylitis (AS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Early-stage AS
- Advanced-stage AS
- 6.7. Global Axial Spondyloarthritis (axSpA) Market, Sub-Segmentation Of Non-Radiographic Axial Spondyloarthritis (nr-axSpA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Symptomatic nr-axSpA
- Asymptomatic nr-axSpA
7. Axial Spondyloarthritis (axSpA) Market Regional And Country Analysis
- 7.1. Global Axial Spondyloarthritis (axSpA) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Axial Spondyloarthritis (axSpA) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Axial Spondyloarthritis (axSpA) Market
- 8.1. Asia-Pacific Axial Spondyloarthritis (axSpA) Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Axial Spondyloarthritis (axSpA) Market
- 9.1. China Axial Spondyloarthritis (axSpA) Market Overview
- 9.2. China Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Axial Spondyloarthritis (axSpA) Market
- 10.1. India Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Axial Spondyloarthritis (axSpA) Market
- 11.1. Japan Axial Spondyloarthritis (axSpA) Market Overview
- 11.2. Japan Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Axial Spondyloarthritis (axSpA) Market
- 12.1. Australia Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Axial Spondyloarthritis (axSpA) Market
- 13.1. Indonesia Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Axial Spondyloarthritis (axSpA) Market
- 14.1. South Korea Axial Spondyloarthritis (axSpA) Market Overview
- 14.2. South Korea Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Axial Spondyloarthritis (axSpA) Market
- 15.1. Western Europe Axial Spondyloarthritis (axSpA) Market Overview
- 15.2. Western Europe Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Axial Spondyloarthritis (axSpA) Market
- 16.1. UK Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Axial Spondyloarthritis (axSpA) Market
- 17.1. Germany Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Axial Spondyloarthritis (axSpA) Market
- 18.1. France Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Axial Spondyloarthritis (axSpA) Market
- 19.1. Italy Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Axial Spondyloarthritis (axSpA) Market
- 20.1. Spain Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Axial Spondyloarthritis (axSpA) Market
- 21.1. Eastern Europe Axial Spondyloarthritis (axSpA) Market Overview
- 21.2. Eastern Europe Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Axial Spondyloarthritis (axSpA) Market
- 22.1. Russia Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Axial Spondyloarthritis (axSpA) Market
- 23.1. North America Axial Spondyloarthritis (axSpA) Market Overview
- 23.2. North America Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Axial Spondyloarthritis (axSpA) Market
- 24.1. USA Axial Spondyloarthritis (axSpA) Market Overview
- 24.2. USA Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Axial Spondyloarthritis (axSpA) Market
- 25.1. Canada Axial Spondyloarthritis (axSpA) Market Overview
- 25.2. Canada Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Axial Spondyloarthritis (axSpA) Market
- 26.1. South America Axial Spondyloarthritis (axSpA) Market Overview
- 26.2. South America Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Axial Spondyloarthritis (axSpA) Market
- 27.1. Brazil Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Axial Spondyloarthritis (axSpA) Market
- 28.1. Middle East Axial Spondyloarthritis (axSpA) Market Overview
- 28.2. Middle East Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Axial Spondyloarthritis (axSpA) Market
- 29.1. Africa Axial Spondyloarthritis (axSpA) Market Overview
- 29.2. Africa Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Axial Spondyloarthritis (axSpA) Market Competitive Landscape And Company Profiles
- 30.1. Axial Spondyloarthritis (axSpA) Market Competitive Landscape
- 30.2. Axial Spondyloarthritis (axSpA) Market Company Profiles
- 30.2.1. Johnson and Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Merck and Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
31. Axial Spondyloarthritis (axSpA) Market Other Major And Innovative Companies
- 31.1. Novartis AG
- 31.2. Sanofi S.A
- 31.3. Bristol-Myers Squibb Company
- 31.4. AstraZeneca plc.
- 31.5. Abbott Laboratories
- 31.6. GSK plc.
- 31.7. Eli Lilly and Company
- 31.8. Takeda Pharmaceutical Company Limited
- 31.9. Gilead Sciences Inc.
- 31.10. Teva Pharmaceutical Industries Ltd.
- 31.11. Regeneron Pharmaceuticals Inc.
- 31.12. Biogen Inc.
- 31.13. Vertex Pharmaceuticals Incorporated
- 31.14. UCB S.A.
- 31.15. Boehringer Ingelheim International GmbH.
32. Global Axial Spondyloarthritis (axSpA) Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Axial Spondyloarthritis (axSpA) Market
34. Recent Developments In The Axial Spondyloarthritis (axSpA) Market
35. Axial Spondyloarthritis (axSpA) Market High Potential Countries, Segments and Strategies
- 35.1 Axial Spondyloarthritis (axSpA) Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Axial Spondyloarthritis (axSpA) Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Axial Spondyloarthritis (axSpA) Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
